Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

This study is testing whether adding a drug called pyrotinib (a targeted therapy) after completing standard treatment for HER2-positive early breast cancer can reduce the chances of the cancer coming back, particularly in women who still had cancer cells remaining after their pre-surgery chemotherapy. **You may be eligible if:** - You are a woman aged 18–70 with HER2-positive early breast cancer (Stage IIA–III) - You completed chemotherapy plus the drug trastuzumab before surgery - Cancer cells were still found in your breast or lymph nodes after surgery - You have already received or are receiving the standard duration of trastuzumab therapy - Your blood counts and organ function are adequate **You may NOT be eligible if:** - Your cancer had no remaining cells at the time of surgery (complete pathologic response) - You have had a recurrence or distant spread of disease - You have significant heart problems or other conditions making this treatment unsafe Talk to your doctor to see if this trial is right for you.